StreetAlpha.app
Home › Stocks › NAGE

Niagen Bioscience, Inc. (NAGE)

Healthcare
$2.04
▲ +1.49%
LAST CLOSE · NOV 17

Niagen Bioscience makes Tru Niagen dietary supplements and supplies the Niagen ingredient to food makers and pharmaceutical facilities. It last closed at $2.04 on Nov 17, up 1.49% on the day. The average 12-month price target from 2 analysts is $6.50 (+218.6% from the last close), with a high of $7.00 and a low of $6.00.

AI Auto Pilots
Is NAGE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$122.3M
−1.9% vs a year ago
Net income
$10.2M
−49.9% vs a year ago
EPS (diluted)
$0.12
−50.0% vs a year ago
Gross margin
63.9%
$78.1M gross profit
Valuation
Market cap
$161.6M
79.2M shares
P/E
17.0
Price over 12 month EPS
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$69.5M
At Sep 30
Shareholder equity
$83.1M
Buybacks
$5.4M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $67.4M$67.4MFY2021FY2022: $72.0M$72.0MFY2022FY2023: $83.6M$83.6MFY2023FY2024: $99.6M$99.6MFY2024FY2025: $129.4M$129.4MFY2025

From NAGE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated NAGE in the past 90 days, not enough for a consensus
Average 12-month target
$6.50
▲ 218.6% upside

Based on 2 analysts who set a price target on NAGE in the past 90 days. The average target is $6.50, with a high of $7.00 and a low of $6.00, compared with the last close of $2.04.

Low $6.00Avg $6.50High $7.00
Blue marker: last close $2.04
Highest target$7.00
Average target$6.50
Lowest target$6.00
Latest rating changes
Freedom BrokerMaintained
Nov 6Buy$6
Canaccord GenuityTarget lowered
Nov 6Buy$9 → $7
Canaccord GenuityMaintained
Oct 31Buy$9
DateFirmActionRatingPrice target
Nov 6Freedom BrokerMaintainedBuy$6
Nov 6Canaccord GenuityTarget loweredBuy$9 → $7
Oct 31Canaccord GenuityMaintainedBuy$9
Loading…

Seasonality

How NAGE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NAGE in the last 90 days.

Loading…

See today’s whale options flow across the market →

NAGE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●64 buying vs 70 selling
  • ▼Held by funds -2.5 pts
  • ▼Funds holding -17
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding123140−12.1%
In funds' top 1000–
Held by funds38.1%40.7%−2.5 pts
New / increased15 / 4924 / 38+3.2%
Reduced / sold out39 / 3160 / 26−18.6%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NAGE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAGE is in one of them and how their past NAGE trades turned out.

NAGE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NAGE in an article yet. Here's the latest on the wider market.

About Niagen Bioscience

Niagen Bioscience is a bioscience company based in Los Angeles, California, focused on healthy aging. It sells Tru Niagen dietary supplements to consumers directly and through online marketplaces and distribution partners in many countries. It also supplies its Niagen ingredient, a form of vitamin B3, to food and supplement makers and to outsourcing facilities that prepare injectable products. Its pharmaceutical work on NAD+ precursors is still in research and development and does not yet generate revenue.

Headquarters
Los Angeles, CA